Safety and preliminary efficacy of mesenchymal stromal cell (ORBCEL-M Cell) therapy in diabetic kidney disease: a randomized clinical trial (NEPHSTROM)

Norberto Perico, Giuseppe Remuzzi, Matthew D Griffin, Paul Cockwell, Alexander P Maxwell, Federica Casiraghi, Nadia Rubis, Tobia Peracchi, Alessandro Villa, Marta Todeschini, Fabiola Carrara, Bernadette A Magee, Piero L Ruggenenti, Stefano Rota, Laura Cappelletti, Veronica McInerney, Tomás P Griffin, Md Nahidul Islam, Martino Introna, Olga PedriniJosée Golay, Andrew A Finnerty, Jon Smythe, Willem E Fibbe, Stephen J Elliman, Timothy O'Brien, NEPHSTROM Trial Consortium

Research output: Contribution to journalArticlepeer-review

16 Citations (Scopus)
85 Downloads (Pure)

Abstract

Background
Systemic therapy with mesenchymal stromal cells (MSCs) may target maladaptive processes involved in diabetic kidney disease (DKD) progression. However, clinical translation of this approach has been limited.

Methods
The Novel Stromal Cell Therapy for Diabetic Kidney Disease (NEPHSTROM) study, a randomized, placebo-controlled phase 1b/2a trial, assesses safety, tolerability, and preliminary efficacy of next-generation bone marrow–derived, anti-CD362–selected, allogeneic MSCs (ORBCEL-M) in adults with type 2 diabetes and progressive DKD. This first, lowest-dose cohort of 16 patients at three European sites was randomized (3:1) to receive intravenous infusion of ORBCEL-M (80 × 106 cells, n=12) or placebo (n=4) and followed for 18 months.

Results
At baseline, all participants were negative for anti-HLA antibodies and the measured glomerular filtration rate (mGFR) and estimated GFR (eGFR) were comparable between groups. The intervention was safe and well tolerated. One placebo-treated patient had a quickly resolved infusion reaction (bronchospasm), with no subsequent treatment-related serious adverse events. Two ORBCEL-M recipients died during follow-up of causes deemed unrelated to the trial intervention; one recipient developed low-level anti-HLA antibodies. The median annual rate of kidney function decline following ORBCEL-M compared with placebo did not differ by mGFR but was significantly lower by eGFR estimated by the CKD-EPI and MDRD equations. Immunologic profiling provided evidence of preservation of circulating regulatory T cells, lower natural killer T cells, and stabilization of inflammatory monocyte subsets in those receiving the cell therapy compared with placebo.

Conclusions
Findings indicate safety and tolerability of intravenous ORBCEL-M cell therapy in the trial’s lowest-dose cohort. The rate of decline in eGFR (but not mGFR) over 18 months was significantly lower among those receiving cell therapy compared with placebo. Further studies will be needed to determine the therapy’s effect on CKD progression.
Original languageEnglish
Pages (from-to)1733-1751
Number of pages19
JournalJournal of the American Society of Nephrology
Volume34
Issue number10
Early online date10 Aug 2023
DOIs
Publication statusPublished - Oct 2023

Fingerprint

Dive into the research topics of 'Safety and preliminary efficacy of mesenchymal stromal cell (ORBCEL-M Cell) therapy in diabetic kidney disease: a randomized clinical trial (NEPHSTROM)'. Together they form a unique fingerprint.

Cite this